Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus UNITHROID.
LEVOTHYROXINE SODIUM vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone